Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1444-1448

  Le Bras, Fabien ^a   Sebert, Marie ^a   Kelaidi, Charikleia ^a,b   Lamy, Thierry ^a,c   Dreyfus, François ^a,d   Delaunay, Jacques ^a,e   Banos, Anne ^a,f   Blanc, Michel ^a,g   Vey, Norbert ^a,h   Schmidt, Aline ^a,i   Visanica, Sorin ^a,j   Eclache, Virginie ^a,k   Turlure, Pascal ^a,l   Beyne Rauzy, Odile ^a,m   Guerci, Agnès ^a,n   Delmer, Alain ^a,o   de Botton, Stéphane ^a,p   Rea, Delphine ^a,q   Fenaux, Pierre ^a,k,r   Adès, Lionel ^a,k,r  

^a Groupe Francophone des Myélodysplasies GFM   (France)

^b G Papanikolaou Hospital   (Greece)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Hôpitaux de Paris ^*  (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f CH cote basque   (France)

^g Service hématologie Chambéry   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CHRU Angers   (France)

^j Hôpital de Mercy   (France)

^k AVICENNE HOSPITAL   (France)

^l DUPUYTREN UNIVERSITY HOSPITAL   (France)

^m TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁿ CHU NANCY BRABOIS   (France)

^o SERVICE DE DERMATOLOGIE   (France)

^p INSTITUT GUSTAVE ROUSSY   (France)

^q SAINT LOUIS HOSPITAL   (France)

^r Institut Gustave Roussy   (France)

more..

Author keywords

Del 5q syndrome; Lenalidomide; Myelodysplasia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT; LENALIDOMIDE;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CANCER GROWTH; CAUSE OF DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OTITIS; PHLEBITIS; PREDICTION; PRIORITY JOURNAL; PRURITUS; SKIN INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RISK FACTORS; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80053956542     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.034     Document Type: Article

References (13)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
3. Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004, 18:113-119.
4. Giagounidis A.A., Germing U., Wainscoat J.S., Boultwood J., Aul C. The 5q- syndrome. Hematology 2004, 9:271-277.
5. Van den Berghe H., Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 1997, 94:1-7.
6. Kelaidi C., Park S., Brechignac S., Mannone L., Vey N., Dombret H., et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008, 32:1049-1053.
7. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
8. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
9. Sekeres M.A., Maciejewski J.P., Giagounidis A.A., Wride K., Knight R., Raza A., et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008, 26:5943-5949.
10. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007, 104:11406-11411.
11. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
12. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
13. Giagounidis A., Fenaux P., Mufti G.J., Muus P., Platzbecker U., Sanz G., et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008, 87:345-352.